Fatigue in Newly Diagnosed Inflammatory Bowel Disease

Tore Grimstad1, Katrine B. Norheim1, Kjetil Isaksen1, Kristian Leitao1, Anne K. Hetta1, Arne Carlsen1, Lars N. Karlsen1, Inger Marie Skoie2, Lasse Gøransson1, Erna Harboe1, Lars Aabakken3, Roald Omdal1,4

1Department of Medicine, Stavanger University Hospital, Stavanger, Norway 2Department of Dermatology, Stavanger University Hospital, Stavanger, Norway 3Oslo University Hospital – Rikshospitalet, Oslo, Norway 4Department of Clinical Medicine, University of Bergen, Bergen, Norway

Corresponding author: Tore Grimstad, MD, PhD, Stavanger University Hospital, Box 8100, 4068 Stavanger, Norway. Phone: +47 51519388; Mobile phone: +47 90921650; Fax: +47 51519923; Email: tore.bjorn.grimstad@sus.no

Abstract

Background and Aims: The present study investigated the prevalence and severity of fatigue in patients with newly diagnosed and untreated ulcerative colitis (UC) and Crohn’s disease (CD) and examined relevant disease variables that may influence the severity of fatigue.

Methods: Eighty-one patients with inflammatory bowel disease (IBD) (60 with UC and 21 with CD) were assessed for fatigue using two fatigue instruments: the Fatigue Severity Scale (FSS) and a fatigue visual analogue scale (fVAS). Cut-off for fatigue was defined as ≥4 for FSS and ≥50 for fVAS. Results were compared with fatigue scores from age- and gender-matched healthy individuals. Disease activity was assessed by symptom scores using the Mayo score in UC patients and the Harvey–Bradshaw index for CD patients, as well as C-reactive protein (CRP) and faecal calprotectin.

Results: The prevalence of fatigue based on FSS and fVAS was 47 and 42%, respectively, in UC and 62 and 48% in CD. In multivariate regression models, disease activity markers were not associated with fatigue, while a significant relationship was found with age and depression for both fatigue measures.

Conclusions: Close to 50% of patients with IBD reported fatigue at the time of diagnosis. In newly diagnosed patients with active disease, the severity of fatigue was not associated with measures of disease activity.

Key Words: Fatigue; IBD

1. Introduction

Fatigue is increasingly recognized as a substantial phenomenon in many chronic inflammatory diseases, including inflammatory bowel disease (IBD), rheumatoid arthritis and primary Sjogren’s syndrome. Fatigue can be described as an overwhelming sense of tiredness, lack of energy and feeling of exhaustion that is unaffected by prolonged rest. Fatigue is a non-specific, subjective phenomenon that may interfere with emotional, physical and social functions, often leading to social withdrawal and decreased ability to work.
underlying these relationships are still unknown. Also, the management of fatigue in IBD is far from clear.\(^9\)

The aim of the present study was to describe the prevalence and degree of fatigue in a cohort of newly diagnosed and untreated UC and CD patients compared with matched healthy subjects. In addition, we wanted to explore the possible associations between fatigue and depression and/or markers of disease activity.

2. Methods

2.1. Patients

Patients newly diagnosed with IBD were recruited consecutively from the Department of Gastroenterology at Stavanger University Hospital from 1 April 2012 until 31 December 2013. The inclusion criteria were age \(>16\) years and newly diagnosed IBD. Diagnosis of IBD was made after combined clinical, laboratory, endoscopic, histological and radiological evaluation according to international criteria (ECCO guidelines).\(^{11,12}\) The exclusion criteria were previously diagnosed IBD, receiving specific treatment within the last \(10\) years and inability to adhere to the treatment protocol. Patients were included at the time of the index colonoscopy and all study data were collected and recorded within \(3\) days of the colonoscopy. A total of 81 patients (46 males, 35 females) were included in the study, which was registered at ClinicalTrials.gov (NCT01551563).

2.2. Healthy subjects

The control group consisted of \(67\) subjects with no medical complaints who volunteered to fill out the fatigue visual analogue scale (fVAS) and Fatigue Severity Scale (FSS) questionnaires. The healthy subjects were age- and gender-matched with the patients. To reduce the number of control subjects, some individuals served as controls for both UC and CD cases.

2.3. Fatigue assessment

We used the generic fVAS and the FSS instruments\(^{13}\) to assess fatigue severity. The FSS is a unidimensional fatigue instrument in which the patient responds to nine items, each with a score of \(1–7\). The FSS score is the mean score of the nine items, and a higher FSS score indicates more fatigue. An FSS score of \(3\) or \(4\) has previously been used as cut-off for fatigue, and \(\geq 4\) was used in this study as a conservative approach.\(^{14}\) The fatigue VAS was a 100-mm horizontal line with vertical anchors. The wording on the left end (\(0\) mm) was ‘No fatigue’ and that on the right end (\(100\) mm) was ‘Fatigue as bad as it can be’. The presence of fatigue was defined as an fVAS score \(\geq 50\) mm.\(^{15}\) To assess a concomitant depressive state we applied the Hospital Anxiety and Depression Scale (HADS).\(^{16}\) The HADS consists of \(14\) items, seven each for depression (HADS-D) and anxiety (HADS-A). The patients give each item a number from \(0\) to \(3\), and the scores are summed to obtain the anxiety and depression subscales. An HADS-D score \(\geq 8\) was previously found to be adequate as a cut-off for depression and was used in this study.\(^{17}\)

2.4. Evaluation of disease activity

For the symptomatic assessment of IBD disease activity at the time of diagnosis, we used the Mayo score (MS) for UC patients. This score evaluates four items: stool frequency, blood content, the physician’s estimate of disease activity and endoscopic inflammation.\(^{18}\) An MS of \(\geq 2\) and/or an endoscopic subscore of \(\geq 1\) was regarded as active disease. The Harvey–Bradshaw index (HBI) was applied to evaluate symptoms in CD patients. The index incorporates an assessment of general well-being, abdominal pain, and the number of loose stools the previous day, in addition to the presence of a palpable mass in the abdomen and extra-intestinal manifestations, such as arthralgia, fistula and abscesses.\(^{19}\) An HBI of \(\geq 5\) was regarded as active disease.

2.5. Inflammatory markers

At the time of diagnosis, serum C-reactive protein (CRP) (\(\pm 3\) days) and faecal calprotectin (until \(4\) weeks before and \(3\) days after diagnosis) were measured in all patients. A CRP level \(\geq 5 \mu g/mL\) and faecal calprotectin \(\geq 50\) mg/kg were regarded as abnormal and suggestive of inflammatory activity.

2.6. Other blood variables

Haemoglobin and ferritin were measured at the time of diagnosis and analysed at the hospital’s routine laboratory. Iron deficiency was defined as ferritin \(<30 \mu g/L\) if CRP was \(<5\) mg/L or ferritin \(<100 \mu g/L\) if CRP was \(\geq 5\) mg/L.\(^{20}\) As ferritin is an acute-phase protein, cut-off levels for iron deficiency were adjusted in relation to CRP values.

2.7. Outcome measures

Fatigue scores were compared between patients and healthy controls. The prevalence of fatigue, as measured by fVAS and FSS, in the IBD population was calculated using the designated cut-offs for the respective scales. A conservative overall prevalence of fatigue is reported based on the number of patients with results above the cut-off values for fVAS or FSS.

2.8. Statistical analysis

Fatigue scores were compared between patients and healthy controls. The prevalence of fatigue, as measured by fVAS and FSS, in the IBD population was calculated using the designated cut-offs for the respective scales. A conservative overall prevalence of fatigue is reported based on the number of patients with results above the cut-off values for fVAS or FSS.

The normality of the data was tested using the Shapiro–Wilk test. To compare UC and CD patients with healthy subjects, continuous, normally distributed data were analysed by the paired \(t\)-test and non-normally distributed data by the Wilcoxon rank test. To compare the total IBD group with healthy subjects, the Mann–Whitney rank test for unpaired samples was used. For discrete data, Spearman’s \(\chi^2\) test was applied. When establishing regression models for fatigue, variables presumed to influence fatigue were used for UC (MS, CRP, faecal calprotectin), CD (HBI, CRP, faecal calprotectin) and total IBD (CRP, faecal calprotectin, ferritin, HADS-D) and tested by age- and sex-adjusted linear regression. Based on the results of these regression analyses, a fully adjusted model was established for fatigue in the total IBD group. Variables with \(p \leq 0.25\) in age- and sex-adjusted analyses were included in the fully adjusted model. We considered \(p < 0.05\) as significant. Analyses were performed using IBM SPSS statistical software version 21.

2.9. Ethical considerations

The study was approved by the regional ethics committee and carried out in compliance with the principles expressed in the Declaration of Helsinki. All patients provided written informed consent to participate in the study.

3. Results

3.1. Patient characteristics

Ninety-four patients were potentially eligible for study. Ten patients were not included due to lack of personnel, and thus 84 patients were examined for eligibility. One patient was excluded due to psychiatric illness and inability to adhere to the treatment protocol, and two were excluded due to treatment for IBD within the last 10 years.
A total of 81 consecutive patients (46 males, 35 females) were thus included in the study, 60 with UC and 21 with CD. Sixty-seven age- and gender-matched controls with a median (range) age of 34 (15–73) years were included.

The patient characteristics are given in Table 1. There were no missing data. Twenty-nine (48%) of the UC patients and 12 (57%) of the CD patients were iron-deficient. Anaemia was defined as haemoglobin ≤13.4 g/L in males and ≤11.7 g/L in females. Fourteen (23%) of the UC patients and 4 (19%) of the CD patients were anaemic. Fifteen (19%) of the IBD patients were depressed.

3.2. Fatigue
Patients with UC and CD had significantly higher fatigue scores than age- and gender-matched healthy subjects based on both fVAS and FSS (Figures 1 and 2).

Similarly, when comparing all IBD patients with all control subjects, a significantly higher degree of fatigue was found in IBD patients, as measured by both fVAS and FSS (Figure 3A, B). The prevalence of fatigue is given in Table 2.

3.3. Associations between fatigue and disease activity
Age- and sex-adjusted analyses revealed no significant associations between fVAS or FSS scores and MS, CRP or faecal calprotectin in UC patients. Also, no significant associations were found between fVAS or FSS scores and HBI, CRP or faecal calprotectin in the age- and gender-adjusted model for CD (Table 1, Supplementary Data). However, for both UC and CD the FSS increased with elevated symptom scores and faecal calprotectin, although not reaching significance (data not shown).

In the age- and gender-adjusted analyses for the total IBD cohort, fVAS scores from the initial analyses were associated with CRP, ferritin and HADS-D, whereas FSS scores were associated with faecal calprotectin and HADS-D (Table 3). Five patients (three with UC, two with CD) were considered as outliers based on the scatterplot of standard residuals and were excluded from further analyses.

The fully adjusted model for the total IBD group revealed that neither CRP (p = 0.372) nor ferritin (p = 0.101) influenced the fVAS scores. Also, FSS scores were not influenced by faecal calprotectin (p = 0.525) (Table 4). As expected, HADS-D and age were significantly associated with fVAS (p < 0.001 and p = 0.001, respectively) and FSS scores (p < 0.001 and p = 0.02, respectively). Higher HADS-D scores and decreased age were associated with higher fatigue levels (Table 4).

| Table 1. Demographic and clinical characteristics of 81 patients with ulcerative colitis (UC) and Crohn’s disease (CD). |
|-----------------|-----------------|-----------------|
|                 | UC (n = 60)     | CD (n = 21)     | Total (n = 81) |
| Age, years      | 34 (17–71)      | 22 (17–72)      | 31 (17–72)     |
| Males           | 37 (62)         | 9 (43)          | 46 (57)        |
| Ferritin, µg/L  | 82 (7–667)      | 56 (7–1382)     | 71 (7–1382)    |
| Haemoglobin, g/L| 13.6 (1.6)      | 13.9 (1.6)      | 13.5 (1.6)     |
| C-reactive protein, mg/L | 9.5 (1–130) | 9.1 (1–139) | 9.4 (1–139) |
| Faecal calprotectin, mg/kg | 634 (21–3216) | 400 (45–1409) | 615 (21–3216) |
| HBI             | NA              | 5 (1–16)        | NA             |
| MS              | 7 (1–11)        | NA              | NA             |

Results are presented as n (%) for males, mean (SD) for haemoglobin, and median and range for other variables.

HBI, Harvey–Bradshaw index; MS, Mayo score; NA, not applicable.
The main finding in this study is that approximately 50% of patients with IBD suffer from fatigue at the time of diagnosis and that traditional disease activity measures are not associated with this phenomenon. Using conservative cut-offs, the prevalence of fatigue in UC patients is 47% based on the FSS and 42% based on the fVAS. In patients with CD, fatigue is reported by 62% and 48% of patients on the FSS and fVAS, respectively. The percentages are considerably higher than in the healthy subjects, as fatigue was reported by 10% at the most. This difference demonstrates that fatigue is a prevalent and serious problem for patients suffering from IBD. The severity and prevalence of fatigue in newly diagnosed IBD is comparable to that of primary Sjögren’s syndrome and rheumatoid arthritis, and considerably more effort has been put into exploring these issues.21,22 A higher prevalence of fatigue in IBD patients compared with healthy individuals has previously been reported,10 but the use of fatigue as a primary outcome has not been widely investigated. This is the first report of fatigue in an IBD cohort consisting of only newly diagnosed patients not receiving anti-inflammatory or immune-modulating medication.

The reported prevalence of fatigue in previous studies has varied from 41% in patients in remission to 86% in CD patients with active disease,8,23 and from 44 to 64% in patients with different disease activity.7,24 In the current study, disease activity ranged from mild to severe, and the reported fatigue was in line with studies in cohorts involving various grades of disease activity.

The disease activity of IBD (active disease as opposed to remission) has been reported to influence fatigue in the majority of previous studies,8,10,25,26 but we could not confirm these observations. This might be expected, as all patients had active disease. Although the FSS increased with increased signs of inflammation, as measured by symptom scores and faecal calprotectin, these differences did not reach statistical significance (data not shown). Fatigue may be markedly different between patients in remission and those with active disease, but in newly diagnosed patients with active inflammatory disease the association between disease activity and fatigue could be

### Table 2

<table>
<thead>
<tr>
<th></th>
<th>FSS score</th>
<th>p-value&lt;sup&gt;b&lt;/sup&gt;</th>
<th>fVAS score</th>
<th>p-value&lt;sup&gt;b&lt;/sup&gt;</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>≥4 &lt;4</td>
<td>≥50 mm &lt;50 mm</td>
<td></td>
<td></td>
</tr>
<tr>
<td>UC</td>
<td>28 (46.7) 32 (53.3)</td>
<td>&lt;0.001</td>
<td>25 (41.7) 35 (58.3)</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>Healthy subjects</td>
<td>4 (6.7) 56 (93.3)</td>
<td></td>
<td>1 (1.7) 59 (98.3)</td>
<td></td>
</tr>
<tr>
<td>CD</td>
<td>13 (61.9) 8 (38.1)</td>
<td>&lt;0.001</td>
<td>10 (47.6) 11 (52.4)</td>
<td>0.002</td>
</tr>
<tr>
<td>Healthy subjects</td>
<td>2 (9.5) 19 (90.5)</td>
<td></td>
<td>1 (4.8) 20 (95.2)</td>
<td></td>
</tr>
<tr>
<td>All IBD patients</td>
<td>41 (50.6) 40 (49.4)</td>
<td>&lt;0.001</td>
<td>35 (43.2) 46 (56.8)</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>Healthy subjects</td>
<td>4 (6.0) 63 (94)</td>
<td></td>
<td>2 (3.0) 65 (97)</td>
<td></td>
</tr>
</tbody>
</table>

Data are n (%). Some healthy individuals were used as controls for both UC and CD patients.

<sup>a</sup>Defined as FSS score ≥4 or fVAS ≥ 50 mm.

<sup>b</sup>Differences between patients and controls were analysed by the Pearson χ² test.

FSS, Fatigue Severity Scale; fVAS, fatigue visual analogue scale; IBD, inflammatory bowel disease.

### Table 3

<table>
<thead>
<tr>
<th>fVAS</th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>β</td>
<td>R²</td>
<td>p-value</td>
<td>β</td>
</tr>
<tr>
<td>CRP</td>
<td>0.15</td>
<td>0.06</td>
<td>0.24</td>
<td>&lt;0.01</td>
</tr>
<tr>
<td>Faecal calprotectin</td>
<td>&lt;0.01</td>
<td>0.06</td>
<td>0.27</td>
<td>&lt;0.01</td>
</tr>
<tr>
<td>Ferritin</td>
<td>0.05</td>
<td>0.07</td>
<td>0.13</td>
<td>&lt;0.01</td>
</tr>
<tr>
<td>HADS-D</td>
<td>4.56</td>
<td>0.44</td>
<td>&lt;0.001</td>
<td>0.32</td>
</tr>
</tbody>
</table>

<sup>a</sup>Five patients were excluded as outliers.

IBD, inflammatory bowel disease; fVAS, fatigue visual analogue scale; FSS, Fatigue Severity Scale; CRP, C-reactive protein; HADS-D, Hospital Anxiety and Depression Scale depression subscale.

### 4. Discussion

The main finding in this study is that approximately 50% of patients with IBD suffer from fatigue at the time of diagnosis and that traditional disease activity measures are not associated with this phenomenon. Using conservative cut-offs, the prevalence of fatigue in UC patients is 47% based on the FSS and 42% based on the fVAS. In patients with CD, fatigue is reported by 62% and 48% of patients on the FSS and fVAS, respectively. The percentages are considerably higher than in the healthy subjects, as fatigue was reported by 10% at the most. This difference demonstrates that fatigue is a prevalent and serious problem for patients suffering from IBD. The severity and prevalence of fatigue in newly diagnosed IBD is comparable to that of primary Sjögren’s syndrome and rheumatoid arthritis, and considerably more effort has been put into exploring these issues.21,22

A higher prevalence of fatigue in IBD patients compared with healthy individuals has previously been reported,10 but the use of fatigue as a primary outcome has not been widely investigated. This is the first report of fatigue in an IBD cohort consisting of only newly diagnosed patients not receiving anti-inflammatory or immune-modulating medication.

The reported prevalence of fatigue in previous studies has varied from 41% in patients in remission to 86% in CD patients with active disease,8,23 and from 44 to 64% in patients with different disease activity.7,24 In the current study, disease activity ranged from mild to severe, and the reported fatigue was in line with studies in cohorts involving various grades of disease activity.

The disease activity of IBD (active disease as opposed to remission) has been reported to influence fatigue in the majority of previous studies,8,10,25,26 but we could not confirm these observations. This might be expected, as all patients had active disease. Although the FSS increased with increased signs of inflammation, as measured by symptom scores and faecal calprotectin, these differences did not reach statistical significance (data not shown). Fatigue may be markedly different between patients in remission and those with active disease, but in newly diagnosed patients with active inflammatory disease the association between disease activity and fatigue could be

![Figure 3](http://ecojcc.oxfordjournals.org/)

**Figure 3.** Fatigue VAS (A) and FSS (B) measured in the total IBD group (UC and CD; n = 81) compared to 67 age- and gender-matched healthy subjects. Medians and 25th and 75th percentiles are shown. Whiskers indicate range. VAS, visual analogue scale; FSS, Fatigue Severity Scale; IBD, inflammatory bowel disease; UC, ulcerative colitis; CD, Crohn’s disease.
Table 4. Final and optimal multiple regression model for the total IBD group (n = 76)*

<table>
<thead>
<tr>
<th></th>
<th>IVAS</th>
<th>FSS</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>β</td>
<td>p-value</td>
</tr>
<tr>
<td>CRP</td>
<td>0.09</td>
<td>0.37</td>
</tr>
<tr>
<td>Calprotectin</td>
<td>NA</td>
<td>NA</td>
</tr>
<tr>
<td>Ferritin</td>
<td>0.04</td>
<td>0.1</td>
</tr>
<tr>
<td>HADS-D</td>
<td>4.5</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>Age</td>
<td>-0.47</td>
<td>0.001</td>
</tr>
<tr>
<td>Gender</td>
<td>4.66</td>
<td>0.32</td>
</tr>
</tbody>
</table>

Adjusted R²: 0.47 for IVAS and 0.433 for FSS.

*Five patients were excluded as outliers.

IBD, inflammatory bowel disease; IVAS, fatigue visual analogue scale; FSS, Fatigue Severity Scale; CRP, C-reactive protein; HADS-D, Hospital Anxiety and Depression scale depression subscale; NA, not applicable.

Funding

This work was supported by unrestricted grants from AbbVie, Tillotts Pharma and Ferring Pharmaceuticals.

Conflict of Interest

The authors report no conflicts of interest.

Acknowledgements

Merethe Seglem, Olaug Lyche, Anne Brit Hellestø Meling and Inger Johanne Bo are greatly thanked for their efforts administering study visits and registering study data. Ingeborg Krivik is thanked for excellent technical assistance.

Author Contributions

Study concept and design: TG, LA, RO, LNK. Acquisition of data: TG, KI, KL, AC, AKH, LNK, IMS, LG, EH, LA. Analysis and interpretation of data: TG, KBN, RO. Drafting the manuscript: TG, KBN, LA, RO, KI, KL. Critical revision of the manuscript and approval of final manuscript: all authors.

References


35. Lawson MA, McCusker RH, Kelley KW. Interleukin-1 beta converting enzyme is necessary for development of depression-like behavior following intracerebroventricular administration of lipopolysaccharide to mice. *J Neuroinflammation* 2013;10:54.